Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on cladribine tablets − CLARION

Documents

Study protocol

Initial protocol

20180626_MS700568-0002 CLARION protocol v1.0__Redacted

Updated protocol

MS700568_0002-Protocol-Version 6.0_Redacted.pdf

First published: 29/09/2026

MS700568_0002-Protocol-Version 6.0_Redacted.pdf

First published: 29/09/2026

MS700568_0002-Protocol-CLARION-v4.0_Redacted

First published: 22/02/2024

Study results

No information provided.

Study report

No information provided.

Publications

Study publications

The CLARION study design and status update: a long-term, registry-based study e…

The CLARION study: first report on safety findings in patients newly initiating…

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety St…

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

This study has been awarded the ENCePP seal

Conflicts of interest of investigators

Conflict(s) of interest of investigators

Composition of steering group and observers

MS700568-0002 CLARION protocol v1.9_Composition of Steering Committee and Observers

MS700568-0002 CLARION_Composition of Steering Committee_v4.0

Signed code of conduct

2018-0051_Declaraton compliance with Code

ENCePPCoCAnnex3_DeclarationofcompliancewiththeENCePPCodeofConduct__signed_IB_RK_16JUN2021

Signed code of conduct checklist

2018-0051_CoC checklist

ENCePPCoCAnnex2_ChecklistofCodeofConduct__signed IB 11JUN2021

Signed checklist for study protocols

2018-0051_Checklist for Study Protocol

CLARION_v4.0.Checklist for Study Protocol_Redacted